Charles River Laboratories International Inc. (CRL) and American Renal Associates Holdings Inc. (NYSE:ARA) Comparing side by side

Charles River Laboratories International Inc. (NYSE:CRL) and American Renal Associates Holdings Inc. (NYSE:ARA) compete against each other in the Medical Laboratories & Research sector. We will compare them and contrast their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Charles River Laboratories International Inc. 2.14B 3.12 135.38M 4.39 29.06
American Renal Associates Holdings Inc. 817.25M 0.47 15.65M -0.54 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Charles River Laboratories International Inc. and American Renal Associates Holdings Inc.

Profitability

Table 2 provides Charles River Laboratories International Inc. and American Renal Associates Holdings Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Charles River Laboratories International Inc. 6.33% 11.8% 4%
American Renal Associates Holdings Inc. -1.91% 24.3% -1.6%

Liquidity

The current Quick Ratio of Charles River Laboratories International Inc. is 1.3 while its Current Ratio is 1.6. Meanwhile, American Renal Associates Holdings Inc. has a Current Ratio of 1 while its Quick Ratio is 1. Charles River Laboratories International Inc. is better positioned to pay off its short-term and long-term debts than American Renal Associates Holdings Inc.

Dividends

American Renal Associates Holdings Inc. offers an annual dividend of $1.3 per share, bundled with 11.04% dividend yield. No dividend is paid out by Charles River Laboratories International Inc.

Analyst Recommendations

Charles River Laboratories International Inc. and American Renal Associates Holdings Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Charles River Laboratories International Inc. 0 2 4 2.67
American Renal Associates Holdings Inc. 0 0 0 0.00

The consensus price target of Charles River Laboratories International Inc. is $141.5, with potential upside of 1.71%.

Institutional and Insider Ownership

Institutional investors owned 99.1% of Charles River Laboratories International Inc. shares and 97.9% of American Renal Associates Holdings Inc. shares. 1.1% are Charles River Laboratories International Inc.’s share owned by insiders. Comparatively, 39.59% are American Renal Associates Holdings Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Charles River Laboratories International Inc. -5.29% -6.25% 0.8% 10.23% 23.83% 16.68%
American Renal Associates Holdings Inc. -2.95% -21.69% -19.58% 2.55% 11.19% -7.47%

For the past year Charles River Laboratories International Inc. had bullish trend while American Renal Associates Holdings Inc. had bearish trend.

Summary

Charles River Laboratories International Inc. beats American Renal Associates Holdings Inc. on 11 of the 13 factors.

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and development services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening preclinical drug candidates comprising genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for identification of a druggable target through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, which comprise bioanalysis, pharmacokinetics, drug metabolism, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. This segment also offers specialized testing of biologics and devices that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs and chickens used in the manufacture of live viruses. The company serves pharmaceutical and biotechnology companies, contract research organizations, agricultural and chemical companies, life science and veterinary medicine companies, contract manufacturing organizations, medical device companies, diagnostic and other commercial entities, hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.